Theracryf (TCF)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 0.75p
   
  • Change Today:
      0.000p
  • 52 Week High: 3.95p
  • 52 Week Low: 0.72p
  • Currency: UK Pounds
  • Shares Issued: 427.35m
  • Volume: 26,775
  • Market Cap: £3.21m

Theracryf Overview

TheraCryf is a clinical stage therapeutics company developing a new generation of innovative therapeutics in oncology and behavioural brain disorders. TheraCryf’s strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma. The Company’s clinical asset is SFX-01, a patented sulforaphane-based medicine. Chronos’ neuropsychiatry assets use novel chemistry to address highly relevant targets in brain health and have composition of matter patent cover. The Group Company has the expertise to develop and commercialise the combined portfolio.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn n/a n/a
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue n/a n/a
Pr/Book n/a  
Latest F'cast
Revenue n/a n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

Theracryf Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Mar-19 n/a (3.12) (2.70)p n/a n/a n/a n/a 0.0%
31-Mar-20 n/a (3.17) (2.07)p n/a n/a n/a n/a 0.0%
31-Mar-21 0.19 (3.21) (1.82)p n/a n/a n/a n/a 0.0%
31-Mar-22 n/a (3.17) (0.99)p n/a n/a n/a n/a 0.0%
31-Mar-23 0.44 (5.01) (1.47)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Theracryf Company Announcements

Holding(s) in Company 02-May-2024 10:47 RNS
Total Voting Rights 02-May-2024 07:00 RNS
Change of Name 25-Apr-2024 15:46 RNS

Theracryf ShareCast News

Evgen upbeat on start of glioblastoma research p... 26-Oct-2023 ShareCast
Evgen Pharma doses first volunteers in SFX-01 tr... 16-Nov-2022 ShareCast
Evgen starts recruiting volunteers for trial of ... 12-Oct-2022 ShareCast

Latest Theracryf Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 3: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.

 

Theracryf Market Data

Currency UK Pounds
Share Price 0.75p
Change Today 0.000p
% Change 0.00 %
52 Week High 3.95p
52 Week Low 0.72p
Volume 26,775
Shares Issued 427.35m
Market Cap £3.21m

Theracryf Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend
93.51% below the market average93.51% below the market average93.51% below the market average93.51% below the market average93.51% below the market average
74.07% below the sector average74.07% below the sector average74.07% below the sector average74.07% below the sector average74.07% below the sector average
Income Not Available
Growth Not Available

Theracryf Dividends

No dividends found

Trades for 17-May-2024

Time Volume / Share Price
12:35 11,775 @ 0.72p
08:48 15,000 @ 0.72p

Theracryf Key Personnel

CEO Huw Jones
CFO Toni Hänninen

Top of Page